Cargando…

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors

A first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with the aim of disrupting the tumor microenvironment. PATIENTS AND METHODS: A multicenter, open-label, repeated-d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baird, Richard D., Linossi, Constanza, Middleton, Mark, Lord, Simon, Harris, Adrian, Rodón, Jordi, Zitt, Christof, Fiedler, Ulrike, Dawson, Keith M., Leupin, Nicolas, Stumpp, Michael T., Harstrick, Andreas, Azaro, Analía, Fischer, Stefanie, Omlin, Aurelius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196087/ https://www.ncbi.nlm.nih.gov/pubmed/33301375 http://dx.doi.org/10.1200/JCO.20.00596

Ejemplares similares

Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(®) protein MP0250: a preclinical study
por: Rao, Luigia, et al.
Publicado: (2018)

MP0250, a VEGF and HGF neutralizing DARPin(®) molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models
por: Fiedler, Ulrike, et al.
Publicado: (2017)

A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab
por: Fischer, Stefanie, et al.
Publicado: (2022)

Beyond Antibodies: The DARPin(®) Drug Platform
por: Stumpp, Michael T., et al.
Publicado: (2020)

DARPins: Promising Scaffolds for Theranostics
por: Shilova, O. N., et al.
Publicado: (2019)

EHMTI-0250. General practitioners’ experiences with brief intervention for medication-overuse headache: a qualitative study
por: Kristoffersen, ES, et al.
Publicado: (2014)

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications
por: Stahl, Andreas, et al.
Publicado: (2012)

On the prevention of kidney uptake of radiolabeled DARPins
por: Altai, Mohamed, et al.
Publicado: (2020)

LmxM.22.0250-Encoded Dual Specificity Protein/Lipid Phosphatase Impairs Leishmania mexicana Virulence In Vitro
por: Kraeva, Natalya, et al.
Publicado: (2019)

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
por: Rothenberger, Sylvia, et al.
Publicado: (2022)

Unveiling changes in the landscape of patient populations in cancer early drug development
por: Hierro, Cinta, et al.
Publicado: (2016)

Bivalent EGFR-Targeting DARPin-MMAE Conjugates
por: Karsten, Lennard, et al.
Publicado: (2022)

The production of the first functional antibody mimetic in higher plants: the chloroplast makes the DARPin G3 for HER2 imaging in oncology
por: Ehsasatvatan, Maryam, et al.
Publicado: (2022)

Programmable DARPin-based receptors for the detection of thrombotic markers
por: Strittmatter, Tobias, et al.
Publicado: (2022)

MBP-binding DARPins facilitate the crystallization of an MBP fusion protein
por: Gumpena, Rajesh, et al.
Publicado: (2018)

G‐Quadruplex Recognition by DARPIns through Epitope/Paratope Analogy
por: Miclot, Tom, et al.
Publicado: (2022)

Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy
por: Gabriele, Federica, et al.
Publicado: (2023)

P02.50. Naturopathy and yoga based life style intervention for cardiovascular risk reduction in patients with cardiovascular risk factors: a pilot study
por: Nandakumar, B, et al.
Publicado: (2012)

A rapid, site-selective and efficient route to the dual modification of DARPins
por: Moody, Paul, et al.
Publicado: (2014)

EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer
por: van den Brand, Dirk, et al.
Publicado: (2020)

In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions
por: Pratsinis, Manolis, et al.
Publicado: (2021)

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors
por: Rodon, Jordi, et al.
Publicado: (2018)

Drug Export Pathway of Multidrug Exporter AcrB Revealed by DARPin Inhibitors
por: Sennhauser, Gaby, et al.
Publicado: (2007)

In Vivo Binding and Retention of CD4-Specific DARPin 57.2 in Macaques
por: Pugach, Pavel, et al.
Publicado: (2010)

P13-06. DARPin-based microbicide strategies to block HIV entry
por: Mann, A, et al.
Publicado: (2009)

Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
por: Guillard, Sandrine, et al.
Publicado: (2017)

Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape
por: Shramova, Elena, et al.
Publicado: (2020)

Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs
por: Schilling, Johannes, et al.
Publicado: (2021)

A DARPin-based molecular toolset to probe gephyrin and inhibitory synapse biology
por: Campbell, Benjamin FN, et al.
Publicado: (2022)

The lyophilized chloroplasts store synthetic DARPin G3 as bioactive encapsulated organelles
por: Ehsasatvatan, Maryam, et al.
Publicado: (2023)

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function
por: Azaro, Analía, et al.
Publicado: (2016)

First observation and measurement of the branching fraction for the decay $B^0_s \to D_s^{*\mp} K^{\pm}$
por: Aaij, Roel, et al.
Publicado: (2015)

HGF Mediates the Anti-inflammatory Effects of PRP on Injured Tendons
por: Zhang, Jianying, et al.
Publicado: (2013)

Tuning the Drug Efflux Activity of an ABC Transporter in vivo by in vitro Selected DARPin Binders
por: Seeger, Markus A., et al.
Publicado: (2012)

DARPins recognize mTFP1 as novel reagents for in vitro and in vivo protein manipulations
por: Vigano, M. Alessandra, et al.
Publicado: (2018)

KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe
por: Bery, Nicolas, et al.
Publicado: (2019)

Thermodynamic Stability Is a Strong Predictor for the Delivery of DARPins to the Cytosol via Anthrax Toxin
por: Becker, Lukas, et al.
Publicado: (2021)

Molecular Dynamics Simulations in Designing DARPins as Phosphorylation-Specific Protein Binders of ERK2
por: Gautam, Vertika, et al.
Publicado: (2021)

Exploring the chemical space of the lysine-binding pocket of the first kringle domain of hepatocyte growth factor/scatter factor (HGF/SF) yields a new class of inhibitors of HGF/SF-MET binding
por: Sigurdardottir, A. G., et al.
Publicado: (2015)

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
por: Gueorguieva, Ivelina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d4tvrteti7j65bcdtf5n30vr4l